Lyra therapeutics reports second quarter 2023 financial results and provides corporate update

-- enlighten i pivotal phase 3 trial of lyr-210 in pre-surgical chronic rhinosinusitis (crs) on track to complete enrollment in the coming weeks, with data expected in 1h 2024 -- -- initial topline results from beacon phase 2 trial of lyr-220 in post-surgical crs now anticipated earlier than expected, in september 2023 --
LYRA Ratings Summary
LYRA Quant Ranking